C-reactive protein is measured by a blood test called the C-reactive protein test. Many infections and inflammatory disorders, such as cancer, cardiovascular disease, arthritis, etc., are detected by this test. A C-reactive Protein test can predict the likelihood that someone may experience a heart attack or stroke. The development of portable bioanalytical tests with high specificity and sensitivity, quick reaction times, and multiplexing capabilities for on-site precise disease diagnosis and monitoring is anticipated to benefit greatly from advancements in nanotechnological techniques.
The market for c-reactive protein testing will grow at a CAGR of 2.4%, from $2.76 billion in 2021 to $3.42 billion in 2030.
The market for c-reactive protein testing is expanding due to rising rates of chronic diseases such as cancer, cardiovascular problems, inflammatory bowel diseases, and arthritis, as well as increased use of CRP testing. For instance, the CDC projects that by the end of 2040, 78 million persons in the United States who are 18 years or above will have been diagnosed with arthritis.
The World Health Organization lists cardiovascular disease as one of the main killers worldwide. C-reactive protein is quite effective at determining a person’s chance of having a heart attack or stroke. By assessing the likelihood of atherosclerosis, C-reactive protein is a reliable diagnostic for spotting CVD. Plaque accumulating in the arteries causes atherosclerosis, a condition that results in inflammation of the artery walls. This has increased the need for speedy and effective diagnostic tools, which has sped up the use of CRP testing to identify cardiovascular disease. Additionally, market revenue growth will be driven by ongoing research into the role of C-reactive protein in cardiovascular illnesses.
The widespread availability of alternative testing methods for diseases with higher accuracy rates, such as the electrocardiogram (ECG) in terms of screening for various cardiac diseases and a variety of other products for other diseases, will impede the market’s overall growth.
New emerging markets will have significant development potential as a result of improved healthcare infrastructure, rising unmet healthcare demand, and increased R&D initiatives. Furthermore, the market for c-reactive protein testing is also being opened up to substantial rivals because of considerable technological advancements in rapid diagnostic kits.
Assay Type Insights
In 2020, immunoturbidimetric tests led the market and accounted for 48.5% of total revenue. In the upcoming years, the use of this approach in a number of chronic cardiac and respiratory illnesses would contribute to the segment’s domination. The sector will likely drive market expansion by providing accurate results thanks to advancements in Chemiluminescence Immunoassay (CLIA) technology.
Disease Type Insights
In 2020, the Cardiovascular Diseases (CVD) category dominated the market, accounting for 21.8% of total revenue. The primary driver of market expansion is a rise in the prevalence of CVDs. A few risk factors for CVDs include a sedentary lifestyle, obesity, hypertension, and diabetes. The most thoroughly investigated noninvasive biomarker for inflammation in CVDs is determined to be a C-reactive protein, and there are already a number of hs-CRP assays on the market.
In 2020, the hospitals segment ruled the market, accounting for 27.2% of total revenue. The increasing penetration of CRP testing in hospitals, particularly in developing nations around the world, can be related to the segment’s growth. The increased prevalence of COVID-19, cardiovascular disease, and cancer-related infections has resulted in an increase in hospital visits and, as a result, the use of CRP testing kits. This will present the market with further growth opportunities.
North America led the C-reactive protein testing market with a revenue share of 39.5% in 2020. The increasing use of cutting-edge technologies and a strong emphasis on clinical research in North America are two factors propelling the market. CRP tests are widely used since cancer is so common in the United States.
The Prostate Cancer Foundation claims that among non-skin cancers, prostate cancer is one of the most prevalent in the United States. Additionally, the PSA test should be included in the yearly digital rectal examination that millions of men in the United States get, according to the American Cancer Society & the American Urological Association.
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Thermo Fisher Scientific, inc.
- Merck KGaAA
- Quest Diagnostics
- BOWDITCH MED, I.N.C.
- HORIBA, Ltd
- Ortho Clinical Diagnostics
- Getein Biotech, Inc.
- Randox Laboratories Ltd.
The market for c-reactive protein testing will grow at a CAGR of 2.4%, from $2.76 billion in 2021 to $3.42 billion in 2030. Key elements driving market revenue growth over the forecast period include growing research into the roles of C-reactive protein in inflammatory pathways, increased number of cardiovascular diseases and autoimmune conditions, and growing adoption of point-of-care (POC) CRP testing in primary healthcare settings.